Mauna Kea Technologies : Light at the end of the endoscope
Mauna Kea is a medtech focused on in vivo microscopic imaging. The group aims to revolutionise diagnosis via its Cellvizio® system. Indeed, Cellvizio® presents a unique value proposition by facilitating the real-time observation of tissues at a microscopic scale and helping physicians to accurately target biopsies. The current share price, which reflects the temporary negative impact of COVID-19 on the company's business, presents an attractive entry point to play the extension o...Mauna Kea Technologies is a global medical device company based in France. Co. is focused on innovations in the field of endomicroscopy (microscopic imaging during endoscopy procedures). Co. is predominately active in the advent of optical biopsy. Co. researches, develops and markets innovative tools to visualize and detect cellular abnormalities during endoscopic procedures. Co.'s flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Co. has marketing authorizations in Thailand, United Kingdom, U.S., Brazil, Chile, South Korea, Poland, Russia and Saudi Arabia.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.